Platform|API|Archive|Contact
Humanexa SignalsPharmaceutical Intelligence
Subscribe
Signals
Regulatory
  • FDA
  • EMA
  • MHRA
  • PMDA
  • Health Canada
Clinical
  • Phase I
  • Phase II
  • Phase III
  • Readouts
  • Enrollment Signals
Competitive
  • Pipeline Tracking
  • Company Moves
  • Asset Intelligence
  • Landscape Reports
Markets
  • Pricing
  • Access
  • Commercial
  • Launch Tracking
M&A Watch
  • Licensing
  • Acquisitions
  • Partnerships
  • Capital Raises
StrategyCatalystsPricing
Humanexa Signals

Data-driven pharmaceutical intelligence for biotech investors, pharma operators, consultants, and intelligence teams.

Powered by Humanexa

Categories

  • Regulatory
  • Clinical
  • Competitive
  • Markets
  • M&A Watch
  • Strategy
  • Catalyst Tracker

Company

  • Pricing
  • Partner with us
  • Subscribe
  • Contact
  • Privacy

Subscribe to Humanexa Signals

Weekly intelligence for pharma decision-makers.

No paywall. No spam. Unsubscribe anytime.

© 2026 Humanexa Signals. All rights reserved.

Intelligence powered by the Humanexa engine.

ClinicalAnesthesiaPain ManagementTrial Update

Study on Dexmedetomidine vs Magnesium Sulphate for Thoracotomy Pain Management

The study compares the efficacy of dexmedetomidine and magnesium sulphate as adjuvants in erector spinae block for thoracotomy pain.

Published: July 6, 2026
Updated: July 6, 2026
Author: Humanexa Intelligence
Therapeutic area: Anesthesia / Pain Management
Asset: Dexmedetomidine
Indication: National Cancer Institute
Trial SummaryCLN

Phase III

National Cancer Institute

Status

Active

Signal Score

8.2

Signal assessment

Signal strength

high

Confidence level

moderate

Signalhigh
Confidencemoderate

Why it matters

This study is significant as it compares two adjuvants in a critical area of postoperative pain management, which could reshape clinical practices and product positioning. The outcomes may lead to changes in treatment protocols, influencing market dynamics for pain management products.

Recommended action

Humanexa recommends Monitor.

Analysis

Monitor trial outcomes and publication of results for insights into best practices in postoperative pain management.

Related companies & assets

Assets

  • Dexmedetomidine →
  • Thoracotomy Pain Management →

Sources & Humanexa intelligence

Source links

  • Study on Dexmedetomidine vs Magnesium Sulphate for Thoracotomy Pain Management ↗

Related Humanexa pages

  • Study on Dexmedetomidine vs Magnesium Sulphate for Thoracotomy Pain Management →

Related signals

Trial SummaryCLN

Phase III

Infectious Disease / COVID-19

Status

Active

Signal Score

8.4

Clinicalhigh signal

FDA Warns of Drug Interaction Reducing Remdesivir Effectiveness in COVID-19 Treatment

The FDA has identified a potential drug interaction that may reduce the effectiveness of remdesivir, an authorized treatment for severe COVID-19.

July 7, 2026Read signal →
Trial SummaryCLN

Phase III

Crohn's disease market

Status

Active

Sponsor

Roche

Signal Score

8.4

Clinicalhigh signal

Phase III Trial of Afimkibart Shows Promise for Moderately to Severely Active Crohn's Disease

A Phase III trial is underway to assess the efficacy and safety of Afimkibart in Crohn's disease patients.

July 7, 2026Read signal →

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.

  1. Home
  2. /Clinical
  3. /Study on Dexmedetomidine vs Magnesium Sulphate for Thoracotomy Pain Management